Shingles vaccine Shingrix has been GlaxoSmithKline’s major growth driver, but during the pandemic, even it couldn’t draw on its full strength. In 2020, Shingrix brought in sales of £1.99 billion…

Earlier this year, Jazz Pharmaceuticals floated a “dramatic” shift to new drug revenue by 2022—a plan buoyed by its own cancer and sleep disorder launches in 2019 and 2020, and a fourth targeted for…

When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened to be a…

As Biogen nears a pivotal FDA decision on its closely watched Alzheimer’s disease drug candidate, other parts of the company’s business are sputtering—outlining just how important aducanumab is for the drugmaker in the near-term.   U.S. sales…

After a recent trial setback, GlaxoSmithKline and partner Sanofi’s COVID-19 vaccine program looks to be a more distant contender in the first wave of immunizations. But as one of the…

Bristol Myers Squibb already launched Zeposia into the crowded multiple sclerosis market. But it’s angling for a new approval where its in-class rivals have never gone—and it has earned a quick FDA review…

On the heels of Novartis licensing BeiGene’s tislelizumab, another China-made PD-1 inhibitor has found itself a new U.S. collaborator in a company that’s just pivoting to immuno-oncology. Coherus BioSciences is…

While supply constraints have hung over the rollout of the AstraZeneca COVID-19 vaccine in Europe, last week, CEO Pascal Soriot offered one way officials could make the most of available doses. And now AZ…